PRIMARY RESULTS OF LONG-TERM DYNAMIC MONITORING OF CHILDREN WITH BRONCHIAL ASTHMA OF UNCONTROLLED SEVERE PERSISTENT COURSE

Autor: L. S. Namazova-Baranova, E. A. Vishnyova, E. A. Dobrynina, A. A. Alekseeva, V. I. Smirnov, J. G. Levina, E. V. Antonova
Jazyk: ruština
Rok vydání: 2017
Předmět:
Zdroj: Педиатрическая фармакология, Vol 13, Iss 6, Pp 554-559 (2017)
Druh dokumentu: article
ISSN: 1727-5776
2500-3089
DOI: 10.15690/pf.v13i6.1668
Popis: Background. Patients registers help obtain the latest information about the clinical course of a disease, safety and effectiveness of the medical technology. Objective: Our aim was to analyze the efficiency and safety of omalizumab with children suffering from uncontrolled severe persistent bronchial asthma (BA) according to the data of the developed register. Methods. A register of patients with severe asthma of uncontrolled course receiving omalizumab in addition to basic therapy has been developed. Results. Results of treatment of 101 children aged 6–17 have been analyzed. The duration of therapy with omalizumab lasted from 1 to 85 months, with a median of 16 (10; 44) months. The drug was used in doses of 75 to 600 mg, with a median of 300 (225; 375) mg. The therapy with omalizumab allowed achieving a better control of the disease (AST test prior to start of therapy — 14 (11; 17) points, in 1 year — 20 (13; 25); p < 0,001); reduction of the volume of daily base therapy (prior to start of therapy, average dose of inhaled corticosteroids in terms of fluticasone was 629 ± 304 mg (n = 15), in 4 years — 524 ± 342 mg; p = 0.065); reduction of the number of aggravations and the need to use short-effectiv 2-agonists. No adverse systemic effects of the introduction of genetically engineered biological drugs have been found. Conclusion. Register of patients with severe persistent asthma can be used as a tool for long-term monitoring and integrated assessment of the efficiency and safety of therapy.
Databáze: Directory of Open Access Journals
Externí odkaz: